Aldosterone, a new appreciation of its role in heart failure (Q34041396)

30 July 2017

1 reference

title

Aldosterone, a new appreciation of its role in heart failure (English)

1 reference

30 July 2017

1 reference

Cha AJ

1

1 reference

30 July 2017

Malecha SE

series ordinal

2

1 reference

30 July 2017

Judge KW

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 September 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

20

1 reference

30 July 2017

issue

9

1 reference

30 July 2017

page(s)

1107-1115

1 reference

Hormones and hemodynamics in heart failure

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Catecholamine-induced cardiomyopathy in multiple endocrine neoplasia. A histologic, ultrastructural, and biochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Structural and biochemical remodelling in catecholamine-induced cardiomyopathy: comparative and ontogenetic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Aldosterone and antialdosterone therapy in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Survey of the attitudes of British physicians to pacing

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Magnesium deficiency and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Mineralocorticoids, hypertension, and cardiac fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Aldosterone and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

The role of nitric oxide in the regulation of aldosterone synthesis by adrenal glomerulosa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Central hypertensive effects of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Brain mineralocorticoid receptor diversity: functional implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Captopril in heart failure. A double blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: A subgroup analysis from the cooperative north scandinavian enalapril survival study (CONSENSUS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.13.1107.35023

10.1592/PHCO.20.13.1107.35023

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference